Aug 12, 2020
Resoundant Expands Its Research Services Footprint
Jun 17, 2020
ASC40 (TVB-2640) Significantly Reduced Liver Fat With a 61% Responder Rate in Phase 2 NASH Trial
Jun 17, 2020
Akero Therapeutics Doses First Patient in Expansion of Phase 2a Trial in NASH
May 26, 2020
Akero Therapeutics To Present At The Jefferies Virtual Healthcare Conference
May 13, 2020
Ascletis' THR- beta Agonist ASC41 Receives Approval for Clinical Trials of NASH Indication
May 07, 2020
Galmed Pharmaceuticals to Report First Quarter 2020 Financial Results and Provide Business Update on Thursday May 14
May 07, 2020
Novel Real-World Data Findings From Ongoing TARGET-IBD Study Published In DDW Proceedings
Mar 31, 2020
Data on NASH Candidate ASC40 to be Presented at EASL ILC 2020
Mar 31, 2020
Data on Sagimet's Lead Candidate TVB-2640 to be Presented at EASL ILC 2020
Mar 23, 2020
Pliant Therapeutics Initiates First-in-Human Clinical Trial of PLN-1474 for the Potential Treatment of Liver Fibrosis
Mar 05, 2020
Zydus Announces World's First Drug for the Treatment of Non-Cirrhotic NASH
Mar 05, 2020
Galmed Pharmaceuticals to Report Fourth Quarter and Year End 2019 Financial Results and Provide Business Update on Thursday March 12
Mar 03, 2020
Lipidio Pharmaceuticals Launches with First Close of Series A Financing
Feb 17, 2020
Ascletis' IND Filing for Its Non-alcoholic Steatohepatitis (NASH) Drug Accepted by NMPA
Feb 06, 2020
ProSciento and Nordic Bioscience Form Strategic Partnership to Develop Translational Biomarkers for Nonalcoholic Steatohepatitis (NASH)
Jan 28, 2020
Enzychem Lifesciences Appoints Dr. Michael Charlton To Its Scientific Advisory Board
Jan 13, 2020
Akero Therapeutics Expands Phase 2a Trial in NASH to Include Cohort of Cirrhotic Patients
Dec 16, 2019
Akero Therapeutics Completes Enrollment in Phase 2a Study in NASH
Nov 19, 2019
Viking Therapeutics Announces Initiation of Phase 2b VOYAGE Study of VK2809 in Patients with Biopsy-Confirmed Non-Alcoholic Steatohepatitis (NASH)
Nov 09, 2019
qFIBS Demonstrates Suitability for Nonalcoholic Steatohepatitis (NASH) Assessment in Clinical Trials and Patient Care with Full Quantification of All Crucial Histopathological Features